Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting


ABSTRACT

Purpose

The incidence of hematologic malignancies during pregnancy is 0.02%. However, this figure is increasing, as women delay conception until a later age. Systemic symptoms attributed to the development of a hematologic cancer may overlap with physiologic changes of pregnancy. A favorable prognosis is contingent upon early diagnosis and treatment. Therefore, a high index of suspicion is required by health care providers. Although timely, accurate diagnosis followed by appropriate staging is essential and should not be delayed due to pregnancy, management guidelines are lacking due to insufficient evidence-based research. Consequently, treatment is delayed, posing significant risks to maternal and fetal health, and potential pregnancy termination. This report provides guidelines for clinical management of hematologic cancers during the perinatal period, which were developed by a multidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics specialist, a neonatologist, and experienced nurses, social workers, and psychologists.

Methods

These guidelines were developed by experts in the field during the first International Consensus Meeting of Prenatal Hematologic Malignancies, which took place in Leuven, Belgium, on May 23, 2014.

Results and Conclusion

This consensus summary equips health care professionals with novel diagnostic and treatment methodologies that aim for optimal treatment of the mother, while protecting fetal and pediatric health.

J Clin Oncol 34:501-508. © 2015 by American Society of Clinical Oncology

Although uncommon, the diagnosis of a hematologic malignancy during pregnancy is a dramatic, traumatic event for the patient, her family, and the medical team, raising therapeutic, ethical, and social dilemmas. The rarity of this event precludes prospective, controlled trials; most available information is based on retrospective cohorts, observations, and case reports. Therefore, it is essential to incorporate current knowledge, expert experience, and information on emerging medications and treatment approaches to provide comprehensive guidelines for managing these patients.

An international consensus panel was organized to review diagnostic and novel therapeutic approaches and to integrate new information into treatment protocols for pregnant women with hematologic cancers. Participants were identified based on scientific and clinical contributions to the field. Researchers and clinicians who focus on the teratogenic, obstetric, and neonatal aspects of cancer therapy were also approached. Each member contributed a section that was merged into a draft, which was circulated to all participants before the meeting in Leuven, Belgium, on May 23, 2014. The draft was revised based on consensus achieved during the meeting. It was then circulated to all authors and revised until final consensus was reached.

Diagnosing a hematologic malignancy encompasses a range of techniques. Pregnancy poses special precautions for their use.

Peripheral lymph node and bone marrow biopsies can be performed safely. Although general anesthesia is considered safe, when it is necessary, the risks and benefits should be weighed carefully.
Abdominal and pelvic imaging for lymphoma staging should rely on nonionizing magnetic resonance imaging (MRI) and ultrasonography techniques, excluding cone-beam computed tomography (CT).

Irradiation-related fetal toxicity seems to occur when fetal exposure exceeds 100 mSv. The radiation exposure associated with chest x-rays and CT examinations is significantly lower than the fetotoxic threshold. However, pelvic and abdominal CT are prohibited due to high fetal exposure. Fluorodeoxyglucose positron emission tomography is not recommended, because it results in pelvic irradiation and placental transfer of [18F]fluorodeoxyglucose, which is considered fetotoxic.

MRI is an important diagnostic tool. Although there is no evidence of harmful fetal effects, many regulatory bodies discourage the use of gadolinium-based compounds during pregnancy due to concerns regarding radiofrequency field and acoustic damage. Recent reviews suggest that MRI can be performed for selected indications. Gadobenate dimeglumine (Multihance, Bracco Pharma, Milan, Italy) and gadodaterol meglumine (Dotarem, Guerbet LLC, Bloomington, IN) are safer than gadolinium, because they are not associated with nephrogenic systemic fibrosis, although studies evaluating their general safety are required.

Although abdominal and pelvic ultrasound are less sensitive than MRI, they are often used as inexpensive, safe, and widely available alternatives during pregnancy. Imaging should be used judiciously, taking into consideration the proposed technique, imaging field, and gestational stage.

GUIDELINES FOR CHEMOTHERAPY

The teratogenic potential of any drug depends on the extent of placental transfer, dose, duration and timing of exposure, and genetic variations in maternal and fetal drug metabolism. Chemotherapy during the first trimester can increase the risk of spontaneous abortion, fetal death, and major malformations by 10% to 20%, particularly when taken 27 to 50 days postconception. Lenalidomide and pomalidomide, the new thalidomide analogs, are teratogenic, whereas cytarabine has lower fetotoxic potential.

The embryo is extremely vulnerable to drug-related teratogenicity during organogenesis (weeks 2 to 8 of gestation). However, some organs and systems, including the eyes, genitalia, hematopoietic system, and CNS, remain vulnerable throughout pregnancy.

The fetal phase (ie, second and third trimesters) is characterized by growth and functional maturation of already formed organs and systems. During this phase, the impact of chemotherapy is less predictable. Although the risk of malformation is decreased, risks of intrauterine growth retardation, preterm delivery, and low birth weight are increased. Hematopoietic suppression and subclinical renal or cardiac dysfunction have been reported, although rarely.

A limited number of drugs are proven human teratogens and are contraindicated during pregnancy. Older-generation alkylators (procarbazine, busulfan, chlorambucil, and nitrogen mustard) have high teratogenic and abortive potential; whereas anthracyclines and vinca alkaloids (vinblastine, vincristine) have the lowest. The antimitabolites aminopterin and methotrexate are teratogenic, whereas cytarabine has lower fetotoxic potential. Thalidomide causes phocomelia and CNS dysmorphology at a frequency of 15% to 100%, particularly when taken 27 to 50 days postconception. Lenalidomide and pomalidomide, the new immunomodulating agents, are also considered teratogenic based on their effect on rats and on the thalidomide experience in humans.

Tretinoin (known as all-trans-retinoic acid [ATRA]) is associated with cardiac, craniofacial, and neurologic malformations (retinoid embryopathy) in up to 85% of cases, if taken during the first trimester.

The increasing use of targeted anticancer therapies has complicated the choice of treatment for pregnant patients because safety data are lacking. Incorporating these new tools during pregnancy is questionable in some instances and contraindicated in others. A plethora of animal studies showed increased teratogenicity with most new drugs. The most common of these, rituximab and the tyrosine kinase inhibitors (TKIs), are discussed in detail within the context of their relevant diseases. Intermediate- to high-dose corticosteroids are often used as bridging therapy, providing symptom management for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), especially during the first trimester.

GUIDELINES FOR RADIOTHERAPY

Treatment of hematologic malignancies is based primarily on chemotherapeutic and biologic agents, whereas radiotherapy is usually used in combination with chemotherapy for HL and NHL. The decision to administer radiotherapy in a prenatal setting is complex. Fetal exposure may cause malformations, growth retardation, and death. Long-term adverse effects, including mental retardation, sterility, and cataracts resulting from cell death due to irreparable DNA damage, are possible, as is childhood cancer, which is thought to arise from incomplete repair of damaged DNA.

The preponderance and severity of these effects depend strongly on fetal dose and gestational stage. Risks of malformation, growth retardation, and mental retardation are highest during the embryonic, organogenesis, and early fetal phases. Hence, radiotherapy is generally contraindicated during the first 15 weeks postconception except under rare circumstances. After that time, the decision depends on individual factors, including radiation energy, modality and volume, proximity to the fetus, and treatment technique. It must be considered that even at later stages, exposure to doses ≥ 100 mSv (especially ≥ 500 mSv) is associated with increased risks of malformation and mental retardation. After 25 weeks, ≤ 1 Sv (1000 mSv) is considered relatively safe, depending on the radiation site.

The probability of childhood cancer is dose dependent, regardless of gestational stage at exposure. A dose of 100 mSv generates a 1% increase in cancer incidence in a population.

A medical physicist should be consulted regarding the estimated fetal dose. Current clinical planning systems are not optimal for estimating doses outside the treatment area. Alternatives such as Monte Carlo simulations or other measurements should be considered.

When the estimated dose is above 100 mSv, an informed decision to treat needs to be made with the patient, using dosimetry analyses provided by the medical physicist. Even if the estimated dose is low, it should be reduced as much as possible in accordance with the ALARA (as low as reasonably acceptable) principle.

The choices of therapeutic modality and technique are important for achieving a low incidental dose. Electron-based treatments generate less scattered dose, but are impractical because they are for superficial targets. Photon-based treatments...
Hematologic Malignancies in Pregnancy

need to be limited to lower energies (< 10 MV) to avoid neutron generation. Newer conformal techniques increase the dose outside the target volume and should be used cautiously. Protons and carbon ions promise an even lower incidental dose and could be future modalities of choice.\(^\text{19}\)

The total dose includes leakage from the head of the radiation device and scattered radiation from the treatment room as well as from inside the patient. The patient should have additional protection against leakage and room scatter. Protective lead aprons should be avoided and patient-specific shielding using bridge construction and/or tertiary shield walls should be used instead.\(^\text{19}\)

In summary, irradiation is not recommended during pregnancy. However, use of involved field irradiation to locations distant from the fetus, ensuring minimal fetal exposure, is an option, taking into consideration gestational stage and the unique clinical scenario.

**MATERNAL SUPPORTIVE CARE**

Chemotherapy complications include nausea, vomiting, allergic reactions, and high risk of infections due to disease- and treatment-induced neutropenia. Antiemetics, including D2 receptor antagonists (metoclopramide)\(^\text{20}\) and serotonin receptor antagonists (ondansetron),\(^\text{21}\) are considered safe.

A review of antibiotic use during pregnancy is beyond the scope of this paper. Generally, aminoglycosides, trimethoprim, and tetracyclines should not be prescribed, whereas macrolides, cephalosporins, penicillin, and metronidazole are probably safe.\(^\text{22}\)

The administration of granulocyte growth factors is probably safe, but data are limited.\(^\text{23}\) Blood and blood products can be transfused safely.\(^\text{24}\)

Pregnancy is a hypercoagulable state in which cancer and chemotherapy administration can increase the risk of venous thromboembolism and placental thrombosis. Low molecular weight heparins (LMWHs), which do not cross the placenta, are probably safe.\(^\text{25}\)

The prognosis for women diagnosed with HL during pregnancy seems excellent. They have similar long-term survival compared with matched, nonpregnant controls.\(^\text{30}\)

**NHL**

The evaluation and management of NHL during pregnancy is complex, partly due to the pathologic and clinical heterogeneity of the disease. Important considerations include establishing a histologic diagnosis, appropriate staging with assessment of tumor burden, type and timing of therapy, and timing of delivery.

Identifying the histologic subtype is an important initial step.\(^\text{25}\) A recent, retrospective series described characteristics and outcomes of 50 patients with NHL during pregnancy.\(^\text{25}\) The most common subtype was diffuse large B-cell lymphoma, constituting 73% of B-cell NHLs and 56% of all NHLs. Notably, 20% of patients had T-cell lymphoma, all of which were peripheral/mature T-cell NHLs.

Despite suboptimal staging (eg, absence of functional imaging such as positron emission tomography), studies of NHL during pregnancy have shown a high incidence of extranodal involvement.\(^\text{33,35}\) Moreover, atypical extranodal sites (vagina, breast, and ovary) are often encountered.\(^\text{35}\)

Table 1 summarizes the recommended management of NHL during pregnancy. The decision to administer antenatal therapy is based on several factors, such as type of NHL (indolent \(v\) aggressive), gestational age, and patient preference. Asymptomatic patients with low tumor burden, indolent NHL may be observed, whereas aggressive subtypes warrant systemic therapy in most patients. However, labor should not be induced to expedite chemotherapy. An overarching goal in the care of all pregnant patients with NHL is delivery at term.\(^\text{36}\) Combination chemotherapy, although relatively safe during the second and third trimesters,\(^\text{37,38}\) is contraindicated in early gestational stages.

NHLs warranting antimetabolite therapy (primary CNS lymphoma and Burkitt's lymphoma) are challenging.\(^\text{39,40}\) Aggressive chemotherapy regimens including antimetabolites during pregnancy have been reported. However, caution is advised regarding

Communication: No conflict of interest.

**Lymphoma**

HL is the most common hematologic cancer during pregnancy, followed by NHL. Diagnosis is often delayed because symptoms mimic those accompanying pregnancy (eg, shortness of breath, fatigue, and night sweats) and imaging studies are obtained infrequently. Chest x-ray, MRI, and ultrasonography are usually used for investigation and disease staging.

**HL**

Few patients diagnosed with HL present with asymptomatic, early stage IA/B or IIA nonmediastinal disease.\(^\text{25}\) In these cases, treatment may be deferred until after delivery, especially if diagnosis is established during the third trimester.

However, most cases require early antepartum treatment. When HL is diagnosed during the first trimester, a regimen based on vinblastine monotherapy followed by classic ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) therapy postpartum, or in case of progression, has been used.\(^\text{26}\) However, this approach has not been validated by other groups.\(^\text{27}\) The limited data available suggest that ABVD may be administered safely and effectively during the latter phases of pregnancy. Although it may be associated with prematurity and lower birth weights, studies have not reported significant disadvantages.\(^\text{25,28}\)

Nonpregnant patients with advanced-stage HL (stage IIB, III, or IV) are typically treated with extended courses of multiagent chemotherapy (ABVD or BEACOPP [bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone]), with or without involved-field radiotherapy.\(^\text{29}\) As in early stage HL, ABVD can be given during the second and third trimesters. Information about the use of BEACOPP during pregnancy is not available. However, given the higher dose of anthracyclines and the inclusion of alkylating agents in this regimen, it should be avoided. Also, caution is advised regarding use of supplemental oxygen if bleomycin has been administered. Brentuximab vedotin administered during organogenesis caused embryofetal lethality and teratogenicity in animals; consequently, the product was assigned Pregnancy Category D (ADCETRIS package insert; Takeda Italia, Cerna, Italy).

**CLINICAL CHARACTERISTICS AND MANAGEMENT OF HEMATOLOGIC MALIGNANCIES**

**Table 1**

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>Management of NHL During Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indolent NHL</td>
<td>Delivery at term</td>
</tr>
<tr>
<td>Aggressive NHL</td>
<td>Combination chemotherapy</td>
</tr>
<tr>
<td>Extranodal sites</td>
<td>Prednisone, methylprednisolone</td>
</tr>
<tr>
<td>CNS Lymphoma</td>
<td>Antiemetics</td>
</tr>
<tr>
<td>Burkitt's Lymphoma</td>
<td>Antimetabolite therapy</td>
</tr>
</tbody>
</table>

Downloaded from ascopubs.org by Universita Degli Studi Di Milano on November 17, 2016 from 159.149.103.009
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
fetal teratogenicity (methotrexate [MTX] syndrome and myelo-suppression).

Hence, they are not recommended, especially before week 20 of gestation.

Rituximab, an IgG1 κ monoclonal antibody, is a backbone of B-cell NHL treatment. It crosses the placenta via a specific, receptor-mediated mechanism. Recent studies suggest transplacental passage increases with gestational age. A retrospective, observational study reported a 58% (90/153) live birth rate after rituximab exposure in utero. The first trimester miscarriage rate was 21%; most occurred when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born prematurely; 11 of them had transient neutropenia, when chemotherapy was coadministered. Twenty-two (24%) infants were born premature...
thrombosis. The next section on myeloproliferative neoplasms contains a detailed discussion on thrombotic risks and management.

For women who present in accelerated phase, the disease pace needs to be carefully monitored and advice offered accordingly. In cases of CML in blast crisis during early pregnancy (which remains an aggressive phase of the disease with a poor prognosis, regardless of TKI therapy), recommended management is similar to that of acute leukemia.

**Myeloproliferative Neoplasms**

This section focuses on essential thrombocytosis (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). The incidence of myeloproliferative neoplasms (MPN) is six of 100,000 to 10 of 100,000 annually. Diagnosis is usually during the sixth or seventh decade of life. However, ET, in particular, peaks in women of reproductive age. Fifteen percent of patients with PV are younger than 40 years of age at diagnosis.

ET is the most common MPN in women of childbearing age. A large meta-analysis of pregnant women with ET reported a live birth rate of 50% to 70%, first trimester loss in 25% to 40%, late pregnancy loss in 10%, placental abruption in 3.6%, and intrauterine growth restriction in 4.5%. Maternal morbidity is rare, but stroke has been reported. Although limited, literature regarding PV and PMF is concordant.

Hydroxyccarbamide (hydroxyurea) and anagrelide should be stopped before conception, with an adequate wash-out period. In the event of a clear indication for cytoreductive therapy, IFN-α should be considered.

Box 1 lists factors that define high-risk pregnancies in women with MPN, based upon clinical experience. Analysis of outcomes in pregnant women with ET suggests that JAK2 V617F increases the risk of loss. However, the strength of the association is not sufficient to recommend an alternative management strategy.

**Management of low-risk pregnancy.** Low-dose aspirin is safe and advantageous in MPN. Unless clearly contraindicated, aspirin (75 mg per day) should be offered throughout pregnancy. For women with PV, venesection may be continued when tolerated to maintain the hematocrit within the gestation-appropriate range.

**Management of high-risk pregnancy.** In high-risk pregnancies, additional treatment includes cytoreductive therapy ± LMWH. If cytoreductive therapy is required, INF-α should be titrated to maintain a platelet count of less than 400 × 10^9/L and hematocrit within appropriate range.

Local protocols regarding interruption of LMWH should be adhered to during labor, and dehystrogenation should be avoided. Of note, platelet count and hematocrit may increase postpartum, requiring cytoreductive therapy. Thromboprophylaxis should be considered 6 weeks postpartum due to increased risk of thrombosis.

**Acute Leukemia**

Acute leukemia, reported in one of 75,000 to one of 100,000 pregnancies, presents multiple medical and ethical challenges. The remarkable anemia, thrombocytopenia, and neutropenia that characterize acute myeloid and lymphoblastic leukemia and impair maternal health and fetal development. Prompt treatment is mandatory. Leukapheresis in the presence of clinically significant evidence of leukostasis can be considered, regardless of gestational stage. For patients diagnosed with acute myeloid leukemia (AML) during the first trimester, pregnancy termination followed by conventional induction therapy (cytarabine/anthracycline) is recommended. Those diagnosed later can receive conventional induction therapy, although this seems to be associated with increased risk of fetal growth restriction and even fetal loss. Notably, neonates rarely experience neutropenia and cardiac impairment unless exposed to lipophilic idarubicin, which should not be used.

Acute promyelocytic leukemia presents a unique scenario in the setting of AML. It is often accompanied by disseminated intravascular coagulation. ATRA, a backbone of acute promyelocytic leukemia therapy, induces differentiation of leukemic cells, but is highly teratogenic during the first trimester. Therefore, pregnancy termination is recommended before conventional ATRA-anthracycline therapy. It demonstrates low teratogenicity after the first trimester and can be used then. Arsenic treatment is highly teratogenic and prohibited throughout gestation.

Although it presents challenges similar to those of AML, acute lymphoblastic leukemia (ALL) raises additional therapeutic issues. It requires prophylactic CNS therapy, including MTX and L-asparaginase, which are fetotoxic. MTX interferes with

**Box 1. Criteria for High-Risk Myeloproliferative Neoplasms During Pregnancy**

Sustained rise in platelet count less than 1500 × 10^9/L.*

Previous venous or arterial thrombosis.

Previous occurrence of one or more hemorrhages attributed to myeloproliferative neoplasms.*

Previous pregnancy complications:

a. Unexplained death of a morphologically normal fetus 10 weeks of gestation or older.

b. At least one premature delivery of a morphologically normal fetus at less than 34 weeks of gestation due to:
   i. Severe preeclampsia or eclampsia defined according to standard criteria.
   ii. Recognized features of placental insufficiency.
   c. Three or more unexplained consecutive miscarriages at less than 10 weeks of gestation, without anatomic, hormonal, or chromosomal abnormalities.
   d. Otherwise unexplained intrauterine growth restriction.
   e. Significant antepartum or postpartum hemorrhage requiring transfusion.

Abnormal uterine artery Doppler at week 20 of gestation (mean pulsatility index > 1.4).

*Indication for interferon only, rather than interferon plus low molecular weight heparin.
organogenesis and is prohibited before week 20 of gestation.\textsuperscript{3,41} L-asparaginase may increase the risk for thromboembolic events attributed to the combination of pregnancy and malignancy. Notably, TKIs, essential for patients with Philadelphia chromosome-positive ALL, are teratogenic.\textsuperscript{45} Given these limitations, women diagnosed with ALL before week 20 of gestation should undergo termination of the pregnancy and conventional treatment. After week 20, conventional chemotherapy can be administered during pregnancy and TKIs postpartum.

Leukemia transfer to the fetus seems remarkably low.\textsuperscript{69} This may be due to a highly protective placental barrier or the elimination of leukemic cells by the immune system.\textsuperscript{70} See Appendix (online only) on rare hematologic malignancies, including hairy cell leukemia, multiple myeloma, and myelodysplastic syndromes.

### PERINATAL AND PEDIATRIC ASPECTS

Maternal hematologic malignancies are associated with miscarriages, thromboembolism, as well as impaired nutrient exchange, blood flow, and oxygen delivery in the intervillous placental spaces due to leukemia cells. This leads to higher rates of fetal growth restriction, premature birth, and perinatal mortality.

Cytotoxic treatment can increase perinatal risks.\textsuperscript{71,72} Transient neonatal myelosuppression, a rare complication, is seen after chemotherapy or rituximab administration near term (ie, after week 34 of gestation).\textsuperscript{73} To avoid such outcomes, a 3-week interval between drug administration and anticipated delivery should be planned to avoid accumulation of cytotoxins in the neonate.\textsuperscript{74}

Accumulating prospective research has not found an association between corticosteroids and increased rates of congenital anomalies. Retrospective studies found a small absolute risk for clefing dysmorphology.\textsuperscript{75} Synthetic corticosteroids cross the placenta in varying amounts\textsuperscript{76} and differ significantly in their ability to enter the fetal circulation.\textsuperscript{77-80} Therefore, those that cross the placenta in smaller amounts, such as prednisolone and methylprednisolone, should be chosen. However, a dose-dependent effect has been observed and use should be limited to the smallest effective dose for the shortest duration. Table 2 includes a summary of these effects.

Fetal growth and morphology should be monitored with ultrasound. The placenta should be examined for metasteses, primarily with leukemia and melanomas.\textsuperscript{81} Placental metastasis necessitates disease upstaging and careful fetal monitoring. Neonates should be assessed by a dysmorphologist and geneticist, and followed up by a pediatrician for physical health, potential cardiotoxicity, pediatric cancer, long-term neurodevelopment, and future fertility.

The varying results produced by studies on the potential cardiotoxicity of anthracyclines indicate a need for additional research. Gziri et al\textsuperscript{82} reported lower normal fractional shortening and mildly thinner left ventricular wall, but normal ejection fraction in children exposed prenatally. However, Aviles and colleagues\textsuperscript{83,84} reported normal cardiac morphology and function in 81 children during 17 years of follow-up.

No association was found between prenatal diagnostic radiation and increased rates of childhood and other cancers in more than 2,000,000 exposed children.\textsuperscript{85,86} Exposure in early infancy has been associated with increased risk for lymphomas (odds ratio 5.14; 95% CI 1.27 to 20.78).\textsuperscript{87} However, considering the wide CI, these findings require replication. The benefits of a timely, accurate maternal diagnosis should be weighed against the low risk of childhood mutagenicity.

Research on long-term neurodevelopment of children exposed to chemotherapy is sparse, but reassuring.\textsuperscript{88,89} Aviles and Neri\textsuperscript{84} found no cognitive, neurologic, or psychologic abnormalities in 84 children prenatally exposed to maternal chemotherapy during 18.7 years of follow-up. Normal fertility and cognitive abilities were documented in 12 second-generation children.\textsuperscript{84} However, a recent prospective study found a 2.5-point decrease in IQ associated with each week of prematurity in children exposed to chemotherapy.\textsuperscript{89} Iatrogenic prematurity should be avoided to prevent impaired neurodevelopment. With the possible exception of acute leukemia, delivery should be at term, whenever possible.

The safety of breastfeeding during chemotherapy should be evaluated based on maternal health and medications used. The LactMed Web site and neonatologist breastfeeding experts should be consulted. When in doubt, breastfeeding is not advised.\textsuperscript{91}

In conclusion, although hematologic malignancies in pregnancy are rare, they introduce clinical, social, ethical, and moral dilemmas to the patient, their family, and physicians. The therapeutic challenge is to preserve maternal health and survival without endangering fetal well-being. Evidence-based data are scarce and collaborative efforts are needed to increase the number of clinical and basic research studies. A multidisciplinary team—including, at minimum, an experienced hematologist/oncologist, a high-risk obstetrics specialist, a neonatologist, as well as experienced nurses,

\begin{table}[h]
\centering
\caption{Summary of the Effects of Corticosteroids During Pregnancy.}
\begin{tabular}{|l|c|c|c|c|c|}
\hline
Corticosteroid & Equivalent Dose, mg* & Anti-Inflammatory Potency† & Biologic Half-Life, Hours & Placental Transfer & Placental Metabolism \\
\hline
Cortisone & 31 & 0.8 & 8-12 & Efficient & Extensive \\
Hydrocortisone & 25 & 1 & 8-12 & Efficient & Extensive \\
Prednisone & 6 & 4 & 12-36 & Efficient & Extensive \\
Prednisolone & 6 & 4 & 12-36 & Poor & Extensive \\
Triamcinolone & 5 & 5 & 12-36 & Efficient & Resistant \\
Methylprednisolone & 5 & 5 & 12-36 & Poor & Extensive \\
Betamethasone & 1 & 25 & 36-72 & Efficient & Resistant \\
Dexamethasone & 1 & 25 & 36-72 & Efficient & Resistant \\
\hline
\end{tabular}
\begin{flushleft}
*When compared with 1 mg of dexamethasone. \\
†When compared with hydrocortisone.
\end{flushleft}
\end{table}
Hematologic Malignancies in Pregnancy

social workers, and psychologists, providing close follow-up—is critical to ensuring optimal maternal and fetal outcomes.

The International Network on Cancer, Infertility and Pregnancy registers all cancers occurring during gestation (www.cancerinpregnancy.org). Patient accrual is ongoing and essential, because registration of new cases and long-term follow-up will improve clinical knowledge and increase the level of evidence.

REFERENCES


AUTHOR CONTRIBUTIONS

Conception and design: Michael Lishner, Irena Nulman, Kristel Van Calsteren, Frederic Amant

Financial support: Frederic Amant

Administrative support: Michael Lishner


Manuscript writing: All authors

Final approval of manuscript: All authors

Disclosures provided by the authors are available with this article at www.jco.org.

© 2015 by American Society of Clinical Oncology

www.jco.org

Downloaded from ascopubs.org by Universita Degli Studi Di Milano on November 17, 2016 from 159.149.103.009
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
Lishner et al


AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Michael Lishner
No relationship to disclose

Irit Avivi
No relationship to disclose

Jane F. Apperley
Consulting or Advisory Role: Ariad, Bristol-Myers Squibb, Novartis, Pfizer
Speakers' Bureau: Ariad, Bristol-Myers Squibb, Novartis, Pfizer
Research Funding: Novartis
Travel, Accommodations, Expenses: Pfizer, Novartis, Bristol-Myers Squibb

Daan Dierickx
No relationship to disclose

Andrew M. Evens
Honoraria: Seattle Genetics, Genentech, Celgene, Millennium
Consulting or Advisory Role: Celgene, Millennium
Speakers' Bureau: Genentech, Celgene
Research Funding: Millennium

Monica Fumagalli
No relationship to disclose

Irena Nulman
No relationship to disclose

Fuat S. Oduncu
No relationship to disclose

Fedro A. Peccatori
No relationship to disclose

Susan Robinson
Honoraria: Novartis

Kristel Van Calsteren
No relationship to disclose

Tineke Vandenbroucke
No relationship to disclose

Frank Van den Heuvel
No relationship to disclose

Frederic Amant
No relationship to disclose
Acknowledgment

The International Consensus Meeting of Prenatal Hematologic Malignancies was sponsored by the European Society of Gynecologic Oncology. J.F.A. is grateful for the support of the National Institute for Health Research Biomedical Research Centre. The manuscript was edited by Faye Schreiber.

Appendix

Rare Hematologic Malignancies


Multiple myeloma. The incidence of multiple myeloma during pregnancy is rare, with 32 cases reported (Caban as-Perianes V, et al: Hematol Oncol 2014, doi:10.1002/hon.2184). Thalidomide is a known teratogen. There is no information on bortezomib and lenalidomide, and they are contraindicated during pregnancy. In contrast, corticosteroids are considered safe during pregnancy and may be used as a bridge until administration of definitive postpartum treatment. For treating skeletal events such as lytic lesions or fractures, only scant information regarding the safety of bisphosphonate use during pregnancy is available. Use of bisphosphonates should be based on risk-benefit considerations, considering the scant data regarding fetal safety (Djokanovic N, et al: J Obstet Gynaecol Can 30:1146-1148, 2008).

Myelodysplastic syndromes. Myelodysplastic syndromes present clonal marrow stem cell disorders, characterized by ineffective hematopoiesis and blood cytopenias, with potential progression/transformation to acute myeloid leukemia (Adès L, et al: Lancet 383:2239-2252, 2014). Therapeutic options in nonpregnant patients include supportive measures and hypomethylating agents. There are no reports on the use of 5-azacitidine during pregnancy; hence it is not recommended.